Copyright: ©Author(s) 2026.
World J Clin Oncol. Nov 24, 2026; 17(11): 124935
Published online Nov 24, 2026. doi: 10.5306/wjco.124935
Published online Nov 24, 2026. doi: 10.5306/wjco.124935
Figure 5 Association between HN1 L expression and adjuvant chemotherapy in colorectal cancer.
A and B: HN1 L expression according to tumor stage (A) and disease status (B) in The Cancer Genome Atlas (TCGA)-colorectal cancer (CRC)cohort; C: Kaplan-Meier analysis of overall survival (OS) according to HN1 L expression in the TCGA-CRC cohort; D: Representative HN1 L immunohistochemical staining categorized as negative, weak, moderate, or strong. HN1 L expression was quantified using HALO software, and patients were divided into HN1 L-high and HN1 L-low groups according to the median H-score; E-F: Kaplan-Meier analyses of OS (E) and disease-free survival (DFS) (F) in the SYSUCC cohort according to HN1 L expression; G: Time-dependent receiver operating characteristic curves evaluating the discriminatory performance of HN1 L expression for DFS at 1, 3, and 5 years; H-I: DFS according to receipt of postoperative adjuvant chemotherapy in patients with high (H) or low (I) HN1 L expression; J: Comparison of serum carbohydrate antigen 19-9 levels between patients who received postoperative adjuvant chemotherapy and those who did not. ᵃP < 0.05 vs stage I; bP < 0.05 vs stage II/III; cP < 0.05 vs partial response/complete response; dP < 0.01 vs patients without adjuvant therapy. AUC: Area under the curve; CA19-9: Carbohydrate antigen 19-9; PR: Partial response; CR: Complete response; SD: Stable disease; PD: Progressive disease.
- Citation: Kang D, Zeng LX, Zhang RX, Ma WJ, Yang R, Wang X. HN1 L promotes colorectal cancer proliferation and migration by inhibiting the Hippo pathway. World J Clin Oncol 2026; 17(11): 124935
- URL: https://www.wjgnet.com/2218-4333/full/v17/i11/124935.htm
- DOI: https://dx.doi.org/10.5306/wjco.124935